• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Wednesday 09/26/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

AIPT

  • 3:56 PM

    MINNEAPOLIS, Sept. 11, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Dr. Amelia Warner of Clinical Trial Concepts has been appointed as the newest member of its Scientific Advisory Board. Amelia Wall Warner, PharmD, RPh, is the Founder and CEO of Clinical Trial Concepts.  She was previously the CEO and founder of the successful Global Specimen Solutions, Inc.

    Read more
  • 9:33 AM

    Helomics Holding Corporation, predicted to generate approximately $3.2 million in revenues by the end of 2018 MINNEAPOLIS, Aug. 14, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three and six months ended June 30, 2018 and provided a business update. Highlights of the second quarter of 2018 and recent weeks include: Signed a definitive merger agreement with Helomics

    Read more
  • 11:34 AM

    MINNEAPOLIS, Aug. 09, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Helomics Corporation, which has a definitive merger agreement with AIPT, has launched its new Precision Oncology Insights platform. This platform provides a personalized oncology roadmap for oncologists and their patients. The initial focus will be on gynecologic cancers, especially ovarian. This unique platform tests living tumor tissue from

    Read more
  • 12:19 PM

    MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has received confirmation from the Börse-Stuttgart Stock Exchange (the “Stuttgart Stock Exchange”) that the Stuttgart Stock Exchange will delist Precision Therapeutics’ stock, traded under the symbol “S1K1” in Germany. The Company contacted the Stuttgart Stock Exchange requesting delisting of any Precision Therapeutics securities on July 23, 2018. The Stuttgart Stock Exchange has formally announced the

    Read more
  • 11:31 AM

    In an Interview with CEOCFO Magazine, CEO Dr. Carl Schwartz Explains how the Company’s Database of Tumors, Artificial Intelligence Technology, and Groundbreaking Method for Growing Human Cancer Cells Makes it a Leader in Personalized Medicine EAGAN, MN / ACCESSWIRE / July 17, 2018 / CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with Dr. Carl Schwartz, President, CEO and Director of Precision Therapeutics Inc (NASDAQ: AIPT). As Dr. Schwartz told CEOCFO’s Bud Wayne, Precision Therapeutics has become

    Read more
  • 4:39 PM

    MINNEAPOLIS , July 12, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that on July 11, 2018 the European Patent Office (“EPO”) granted European Patent No. 2948200  covering the Company’s STREAMWAY® System for automated, direct-to-drain medical fluid disposal, which is sold through the Company’s Skyline Medical division. The Company is seeking national validation of its European patent in 11 European countries, including

    Read more
Public Wire Banner